Stockreport

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting [Yahoo! Finance]

Verrica Pharmaceuticals Inc.  (VRCA) 
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am Check Earnings Report
PDF tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support [Read more]